Identity and synonyms
Catalog label is recorded; analytical identity and equivalence are not established.
Nonpeptide agent · Amino acid or derivative
Detailed molecular class: Nonpeptide agent; see mechanism for subtype
Supplied sequence or chemical reference
PubChem CID: 12035
Molecular formula: C5H9NO3S
IUPAC: (2R)-2-acetamido-3-sulfanylpropanoic acid
Source: PC-NAC
Database chemical reference; does not certify supplier vial, salt, isomer or formulation.
Mechanism
N-acetylcysteine provides thiols/glutathione precursor; an amino-acid derivative, not a peptide.
Evidence and critical reading
Reported scientific and empirical uses
Respiratory function
Acetaminophen-poisoning antidote in specific formulations; mucolytic uses depend on product/country.
Human evidence
Antidote rationale does not validate nonspecific “detox”, longevity or amino-acid blends. Hospital intravenous evidence is not equivalent to an oral supplement.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
Antidote rationale does not validate nonspecific “detox”, longevity or amino-acid blends. Hospital intravenous evidence is not equivalent to an oral supplement.
Antidote rationale does not validate nonspecific “detox”, longevity or amino-acid blends. Hospital intravenous evidence is not equivalent to an oral supplement.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
US: the cited IV acetylcysteine formulation is an antidote to prevent/reduce acetaminophen-overdose liver injury per labeling. This is not wellness “detox” approval.
Adverse effects and unknowns
IV formulation can cause serious hypersensitivity, hypotension and bronchospasm; fluid overload also matters. Routes are not interchangeable.
Contraindications
The cited IV label contraindicates previous acetylcysteine hypersensitivity.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
A hospital antidote label does not validate physical/pharmacologic compatibility with a commercial amino-acid blend.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
N-acetylcysteine · 677 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT05294744 · Utility of the Use of N-acetylcysteine Associated With Conventional Treatment in Patients With Severe Acute Alcoholic Hepatitis (Maddrey> 32)Registry status: CompletedLast update posted: October 16, 2026Query verification: October 16, 2026
NCT07877441 · Antioxidant Supplementation and Muscle Recovery From DOMS in Trained WomenRegistry status: CompletedLast update posted: October 16, 2026Query verification: October 16, 2026
NCT07875322 · Silymarin Versus N-Acetylcysteine as Protective Effect Against Anti-tuberculosis Drugs Induced Liver Injury.Registry status: Not yet recruitingLast update posted: October 15, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PC-NAC
PubChem N-acetyl-L-cysteine (CID 12035)
October 16, 2026
- REG-NAC
DailyMed: Acetylcysteine injection
October 16, 2026
- SEARCH-PUBMED-nac
October 16, 2026